Selpercatinib

Active substance
Selpercatinib
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Thyroid cancer
Extended indication
Patients With RET-Mutant Medullary Thyroid Cancer

1. Product

Manufacturer
Eli Lilly
Mechanism of action
Tyrosine kinase inhibitor
Route of administration
Oral
Therapeutical formulation
Capsule
Budgetting framework
Intermural (MSZ)
Additional comments
Tyrosine kinase inhibitor met antineoplastische eigenschappen. Potente, selectieve remmer van de RET-kinase, ontwikkeld om de ATP-bindingsite vd RET-kinase te blokkeren. Zo wordt de ‘down stream’ signalling pathway geremd.

2. Registration

Registration route
Centralised (EMA)
Submission date
February 2020
Expected Registration
March 2021
Orphan drug
No
Registration phase
Registration application pending

3. Therapeutic value

Current treatment options
RET fusie-positieve NSCLC: Carboplatin/Cisplatin + Pemetrexed +/- Pembrolizumab.RET-gemuteerde medullaire thyroïd kanker: Cabozantinib/vandetanib
Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
2 times a day
References
NCT04211337 (LIBRETTO-531)

4. Expected patient volume per year

There is currently nothing known about the expected patient volume.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No
References
adisinsight

9. Other information

There is currently no futher information available.